InsidersTradesSigma
基于 5 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Discover the full record of transactions filed by Heinen Mark, 管理人员. Officer active across 2 companies, notably Better Therapeutics, Inc.. Aggregated, 12 disclosures have been published. Split: 6 buys · 0 sell. Total volume traded: €12k. Activity tracked since 13 December 2021. The latest transaction was filed on 27 March 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 条申报中的 12 条
Heinen Mark is a Dirigeant and Chief Financial Officer at Better Therapeutics, Inc. (XNAS) and Volato Group, Inc. (XNAS). He has 12 filings in total, and across the sampled recent filings, purchases total EUR 12453 and sales total EUR 0, with filings ranging from 2021-11-01 to 2026-03-31. The most frequent transaction nature is Attribution.